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Abstract
Background: Alzheimer’s disease (AD) is the 6th leading cause of death and affects 5.4 million Americans. It
is thought to be caused, in part, by the deposition of β-amyloid plaques in the brain. Intravenous
immunoglobulin (IVIg) is a medication with a reputable safety record that contains natural anti-β-amyloid
(Aβ) antibodies. Decades of research have led to the proposal of IVIg for the treatment of AD.
Method: An exhaustive search of medical literature was conducted. Key words searched included:
intravenous immunoglobulin, Alzheimer’s disease, immunotherapy, and Aβ. Articles were screened to fit
criteria and assessed using the GRADE method.
Results: Three studies met criteria. Study 1 showed at 9, 18, and 36 months, the group treated with IVIg
continuously (n=16) had statistically less decline in cognitive function compared to placebo (n=8). Patients
treated with IVIg 0.4g/kg/2weeks continuously over 36 months showed no decline in ADAS-Cog or ADCS-
CGIC assessments. Study 2 measured Aβ load and cognitive function of 8 patients during 6 months of
therapy, followed by a 3-month washout, and 9 months of resumed therapy. Aβ load was statistically lower at 6
months, returned to baseline after the washout, and was again statistically lower after 9 months of return to
therapy (P<0.003). The mean MMSE increased 2.5 points at 6 months and was unchanged from baseline to
18 months. Study 3 measured Aβ load and cognitive function of 5 patients treated with IVIg at baseline and
after 6 months of treatment. Aβ load decreased in all patients (mean: 30.1%, P<0.05). A slight improvement of
3.7 ± 2.9 points on the ADAS-Cog was calculated at 6 months.
Conclusion: IVIg therapy at a dose of 0.4g/kg/2weeks may be an effective treatment for AD. Limitations of
the studies include low number of subjects, potential bias, and flawed study designs. The very low quality of
evidence makes a definitive conclusion impractical. There is a need for larger, placebo-controlled, randomized,
double-blind clinical trials. The Gammaglobulin Alzheimer Partnership (GAP) study is in progress, and
includes 360+ AD patients, has an appropriate design, and may provide further evidence of the efficacy of
IVIg in AD.
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Abstract   
 
Background:  Alzheimer’s disease (AD) is the 6th leading cause of death and affects 5.4 
million Americans. It is thought to be caused, in part, by the deposition of β-amyloid 
plaques in the brain. Intravenous immunoglobulin (IVIg) is a medication with a reputable 
safety record that contains natural anti-β-amyloid (Aβ) antibodies. Decades of research 
have led to the proposal of IVIg for the treatment of AD. 
Method:  An exhaustive search of medical literature was conducted.  Key words 
searched included: intravenous immunoglobulin, Alzheimer’s disease, immunotherapy, 
and Aβ. Articles were screened to fit criteria and assessed using the GRADE method. 
Results:  Three studies met criteria. Study 1 showed at 9, 18, and 36 months, the group 
treated with IVIg continuously (n=16) had statistically less decline in cognitive function 
compared to placebo (n=8). Patients treated with IVIg 0.4g/kg/2weeks continuously over 
36 months showed no decline in ADAS-Cog or ADCS-CGIC assessments. Study 2 
measured Aβ load and cognitive function of 8 patients during 6 months of therapy, 
followed by a 3-month washout, and 9 months of resumed therapy. Aβ load was 
statistically lower at 6 months, returned to baseline after the washout, and was again 
statistically lower after 9 months of return to therapy (P<0.003). The mean MMSE 
increased 2.5 points at 6 months and was unchanged from baseline to 18 months. Study 3 
measured Aβ load and cognitive function of 5 patients treated with IVIg at baseline and 
after 6 months of treatment. Aβ load decreased in all patients (mean: 30.1%, P<0.05). A 
slight improvement of 3.7 ± 2.9 points on the ADAS-Cog was calculated at 6 months. 
Conclusion:  IVIg therapy at a dose of 0.4g/kg/2weeks may be an effective treatment for 
AD. Limitations of the studies include low number of subjects, potential bias, and flawed 
study designs. The very low quality of evidence makes a definitive conclusion 
impractical. There is a need for larger, placebo-controlled, randomized, double-blind 
clinical trials. The Gammaglobulin Alzheimer Partnership (GAP) study is in progress, 
and includes 360+ AD patients, has an appropriate design, and may provide further 
evidence of the efficacy of IVIg in AD.  
Keywords:  Intravenous immunoglobulin, Alzheimer’s disease, immunotherapy, β-
amyloid 
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Intravenous Immunoglobulin Therapy for the Treatment of 
Alzheimer’s Disease 
BACKGROUND 
 Alzheimer’s disease (AD) is a debilitating, progressive disorder that currently 
affects the lives of 5.4 million Americans and is expected to exceed 100 million 
worldwide by 2050.1,2 It is the sixth leading cause of death in the United States with an 
average life expectancy of five to eight years after diagnosis.1,3 An estimated $200 billion 
will be spent in the United States this year alone to care for adults with this distressing 
condition.1 At this time, providers can do nothing to prevent their patients from 
developing AD, nor can they prescribe anything to cure it or even halt its progression.1,3 
There is an urgent need for a safe and effective therapy.  
 The cause and pathogenesis of Alzheimer’s disease is uncertain.  The two 
currently accepted theories include the deposit of misfolded, amyloid-beta peptide (Aβ) 
plaques in the brain and aggregation of misfolded tau protein in neurofibrillary tangles.2,4 
The Aβ peptide is made of 38-43 amino acids and is produced from the cleavage of the 
amyloid precursor protein (APP). Plaques made of Aβ are found in the diseased brain.5,6 
In healthy individuals, low levels of Aβ can be detected in the serum and cerebral spinal 
fluid (CSF).7,8 In AD, however, it has been suggested that there is either increased 
production or decreased clearance of Aβ, or a specific, neurotoxic formation of Aβ.8,9 
Current research is aimed at strategies to prevent further deposition of Aβ and removing 
the plaques and neurofibrillary tangles that have already been formed.2 
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 Intravenous immunoglobulin (IVIg) is made from pooling the plasma of 
thousands of healthy blood donors which contains natural anti-amyloid antibodies that 
are able to exhibit anti-inflammatory effects. IVIg has been FDA-approved for more than 
25 years for use in patients with autoimmune diseases and immune deficiencies and has a 
reputable safety record.10 The safety of both long-term and high-dose use of IVIg has 
been studied and reported.11-13 One study11 of 293 multiple sclerosis patients receiving 
0.4g/kg body weight for a total of 9 281 IVIg infusions over a period of ten years 
reported no severe adverse events. Minor adverse events occurred in 4.4% of patients the 
first year and the percentage decreased during each subsequent year of therapy. Unlike 
other experimental drugs that have not yet been tested on humans, the specific adverse 
drug reactions to expect from IVIg are well established, and various methods of avoiding 
or combating these reactions are understood.11-14  
 An extensive amount of intriguing research has led to the proposal of IVIg use in 
the treatment of Alzheimer’s disease. Consistent with the Aβ neurotoxicity theory, it was 
discovered that patients with Alzheimer’s disease had lower concentrations of anti-Aβ 
antibodies in their serum compared to healthy adults of the same age.15,16 The naturally 
occurring antibodies in IVIg made it a likely choice for research. Patients treated with 
IVIg for other conditions have significantly lower levels of Aβ in their CSF and 
increased levels of Aβ in their serum, along with increased serum and CSF anti-Aβ 
antibodies.17 In vitro, these antibodies are able to block Aβ fibril formation and prevent 
Aβ-induced neurotoxicity, with the potential benefit of reducing plaque formation and 
loss of neurons.15 In high-quality studies involving mice,18,19 researchers found that, not 
only was IVIg able to cross the blood brain barrier and exude neuro-protective effects, it 
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also promoted phagocytosis and clearance of Aβ plaques already formed. These findings 
strongly support the idea that IVIg could alleviate the neurotoxic load in humans with 
Alzheimer’s disease. Another large, retrospective study20 from a database of 20 million 
people determined that patients who were treated with IVIg at some point in their lives 
had a 42% reduced risk of being diagnosed with Alzheimer’s disease or a related 
disorder.  
 This systematic review will discuss the current clinical trials and the status of the 
therapy to date. It will attempt to examine if IVIg therapy effectively inhibits the 
progression of Alzheimer’s disease.  
METHODS 
 
 An exhaustive search of medical literature using Medline-OVID/PubMed, 
CINAHL, Web of Science, and Google Scholar was conducted using the following 
search terms: intravenous immunoglobulin, immunotherapy, Alzheimer’s disease, and 
beta-amyloid. Animal studies and non-English studies were excluded. The bibliographies 
of relevant articles were further searched to find any other articles that fit the criteria. The 
results were narrowed to include clinical trials in which IVIg was investigated as a 
treatment in a study population with an Alzheimer’s disease diagnosis. Qualifying articles 
were assessed using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE).21 
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RESULTS 
 
 The initial search of databases yielded forty-two results, excluding results from 
Google scholar and bibliography searching. Applying inclusion and exclusion criteria 
resulted in one randomized, double-blinded, placebo-controlled clinical trial and two non-
randomized clinical trials to be analyzed. See Table I. 
Study 1: Phase II Study of IVIg for Treatment of Mild to Moderate Alzheimer’s 
Disease 
 In this placebo-controlled, randomized, double-blind clinical trial,22 the authors 
strive to determine the safety, efficacy and biological mechanisms of action of 
intravenous immunoglobulin (IVIg) in the treatment of 24 patients with probable 
Alzheimer’s disease. The design of this study was found on ClinicalTrials.gov22 and the 
study was listed as “completed”, however the results were not included. Results, 
discussions, and conclusions were published in a variety of sources including a news 
release from the 2008 Alzheimer’s Association International Conference (ICAD),23  the 
2012 ICAD,24 and  a press release from the Baxter website.25 The study published in its 
entirety was not located.  Although some details are absent, this study is still very 
relevant and should be included in this analysis.22-25 
Included patients were over the age of 50, diagnosed with probable AD by the 
National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) criteria, on a stable dose 
of an approved AD drug for at least three months, have an able caregiver, and had 
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neuroimaging studies consistent with the diagnosis. Exclusion criteria included 
conditions that would make the patient more prone to adverse reactions from IVIg.22-25 
 Subjects were randomly assigned to treatment with IVIg (n=16) or placebo (n=8) 
for six months. Each member of the treatment group was randomly assigned to a specific 
dose. The exact doses used were not included in the published data. After six months, all 
subjects were given IVIg with various doses for an additional 12 months. Raters and 
patients were blinded to dose throughout. After 18 months, an additional 18 months of 
treatment at a dose of 0.4g/kg/2weeks was offered to patients so the researchers could 
evaluate three years of IVIg treatment.22-25 
 The primary endpoint studied was cognitive function using the Alzheimer’s 
Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Alzheimer’s Disease 
Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC). Testing was 
carried out at baseline and every three months during the first 18 months and every six 
months during the 18 extension. Adverse events were recorded throughout the entire 
study.22-25 
 Results were evaluated after nine months of treatment, after 18 months of 
treatment, and after three years of treatment. At baseline, groups were statistically similar 
in regards to prognosis. Evaluating nine months of therapy using the ADCS-CGIC, 
results favoring IVIg therapy were statistically significant at three, six, and nine months 
of therapy. Using the ADAS-cog, results favoring IVIg therapy were statistically 
significant at three and nine months of therapy. The group receiving IVIg at a dose of 
0.4g/kg/2weeks showed the greatest outcome. No patient in the placebo group showed 
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comparable improvements. Evaluating 18 months of therapy using the ADCS-CGIC, 
patients randomized to the treatment group received an average of 1.36 percentage points 
higher than patients initially given placebo (P = 0.011). Using the ADAS-cog, the score 
of the treatment group decreased by 9.15 points less than the group initially assigned to 
placebo (P = 0.013). Evaluating three years of treatment includes 5 out of 8 patients 
originally treated with placebo and 11 out of 16 given IVIg at various doses from the time 
of randomization. Patients treated with IVIg 0.4g/kg/2weeks for the full three years had 
the best outcome with no cognitive decline evaluated by the ADAS-cog, ADCS-CGIC or 
any other measures. All patients treated initially with placebo or IVIg at any other dose 
declined significantly.22-25 
 The authors explain that this is the first study to report stabilization of cognitive 
function in treated AD patients over a period of three years. The study suggests that using 
a dose of 0.4g/kg/2weeks continuously yields the best results. The authors also state that 
the limitations of this study include the small number of patients and the bias that can 
occur with an open label extension. The study was funded by the Baxter corporation 
which produces the specific IVIg formulation used.22-25 
Study 2: 18-Month Study of IVIG For Treatment of Mild Alzheimer Disease 
 In this open-label, dose-ranging clinical trial,26 the authors aimed to evaluate the 
safety and dose-related efficacy of IVIg therapy in eight patients with mild Alzheimer’s 
disease (AD). The study was initially designed for six months of treatment with varying 
doses of IVIg followed by a three-month washout period. The positive results of 
treatment led to a nine-month open label extension in which all patients participated.26 
14 
 Patients were included with a diagnosis of probable AD by NINCDS-ADRDA 
criteria, a stable dose of at least one approved AD treatment for three months, and an able 
caregiver. Patients were first given a test dose of IVIg at 0.4g/kg and were then randomly 
assigned to one of four doses of IVIg (0.4g/kg/2weeks, 0.4g/kg/week, 1g/kg/2weeks, or 
2g/kg/4weeks) for six months.26 
 Endpoints studied included dose response, Aβ load, and cognitive function. Dose 
response was determined by an anti-Aβ titer performed before and after the test dose and 
one hour after each subsequent dose. It was observed that the test dose produced a 
statistically significant increase in anti-Aβ titer for all patients (P<0.005, Mann-Whitney 
rand sum test). Also, the anti-Aβ titer correlated positively with the IVIg dose. The Aβ 
load was measured in the serum using the Enzyme-Linked Immunosorbent Assay 
(ELISA) method at baseline, before and after multiple IVIg treatments, weekly 
throughout the first six months, and before and after each dose of the nine-month 
extension. All doses of IVIg resulted in a statistically significant increase in serum Aβ 
(R2 = 0.77, P<0.01). CSF was obtained via lumbar punctures and the Aβ load was 
measured using a Biosource Aβ kit at baseline, one to three months, six months, nine 
months, and eighteen months. After six months of IVIg, all CSF samples showed a 
statistically significant decrease in Aβ (P<0.003). After the three-month washout, no CSF 
samples were statistically different from baseline. After the subsequent nine months of 
IVIg treatment, CSF samples again showed statistically decreased levels of Aβ 
(P<0.003). The initial mean Mini-Mental State Exam (MMSE) score was 23.5. The mean 
MMSE score increased to 24.9 after three months of IVIg and then to 26.0 after six 
months. After the three-month washout, the mean MMSE score decreased to near 
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baseline at 23.9. After nine months of treating again with IVIg, the mean MMSE score 
increased slightly to 24.0. The MMSE was administered by the same person throughout 
the study.26 
 The IVIg infusions were well tolerated with no serous adverse reactions. Minor 
events observed, included headache, chills, diaphoresis, fever, and transient confusion. 
The authors conclude that, while these positive results give hope for the use of IVIg as a 
treatment for Alzheimer’s disease, this study is not definitive, and that, in order for 
clinical recommendations to be made, large, detailed, placebo-controlled, double blinded 
clinical trials must be performed.26 
Study 3: IVIg Against β-Amyloid For The Treatment of Alzheimer’s Disease 
 In this small, prospective clinical trial,27 the authors evaluated the safety and 
efficacy of IVIg treatment in five patients with Alzheimer’s disease (AD). Patients 
included, were from specialty outpatient clinics for those with cognitive disorders and 
met the criteria for clinically probable or clinically possible AD from the NINCDS-
ADRDA criteria. Thorough testing ensured that the patients did not have reversible 
causes of dementia. Patients were allowed to continue current AD medications if they 
were stable for at least six months prior to the study and doses were maintained 
throughout the study.27 
 All patients were given IVIg (Octagam, Octapharma, Langenfeld, Germany) at a 
dose of 0.4g/kg on three consecutive days every four weeks for six months. The study 
was not blinded and no control group was used.27 
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 Endpoints measured included Aβ levels of the CSF and serum and cognitive 
function using the ADAS-cog, Consortium to Establish A Registry for Alzheimer’s 
Disease (CERAD) test, and visual construction ability measurements. Patients and their 
family members were interviewed and any adverse drug reactions were discussed. Aβ 
levels were determined using a sandwich ELISA from samples drawn at baseline and at 
six months. Anti-Aβ titers were measured using the Wilcoxon non-parametric test, from 
samples at baseline and at six months. All patients demonstrated a decrease in CSF Aβ 
concentration, and an increase in serum Aβ concentration, and either stability or 
improvement in measurements of cognitive function from baseline to six months. See 
Table I and II.27 
 All patients completed the study. No serious adverse reactions occurred in the 
study group. Events observed included tension headache, transient confusion, and tooth 
infection. Vital signs, hematologic and biochemical labs, and electrocardiogram (ECG 
findings remained clinically insignificant.27 
 The authors admit that no definitive conclusion can be made following this study 
secondary to the small number of participants, short follow-up, and study method that is 
prone to bias. This study does support the need for larger, blinded, placebo-controlled, 
detailed studies of IVIg as a treatment for AD.27 
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DISCUSSION  
 
 Intravenous Immunoglobulin (IVIg) therapy for patients with Alzheimer’s disease 
is a topic that has understandably drawn attention in the medical community. IVIg is 
already used safely to treat a variety of autoimmune disorders, immune system 
deficiencies, and neurologic conditions including multiple sclerosis and Guillain-Barré 
syndrome.6 Alzheimer’s disease is thought to be caused, in part, by the inappropriate 
deposition of β-amyloid peptide forming plaques in the brain.2-6 The naturally occurring 
anti-Aβ antibodies in IVIg make it a reasonable choice in the treatment of Alzheimer’s 
disease.2  
 Backed by a wealth of supporting evidence, a few researchers conducted clinical 
trials to determine the efficacy of IVIg in the treatment of AD. Patients with AD have an 
average annual decrease of 3-3.5 points on the MMSE2 and 7-11 points in ADAS-cog27. 
These studies consistently found that with IVIg treatment, patients with AD remained 
stable or improved in regards to their cognitive function from six months up to three 
years. The IVIg dose of 0.4g/kg/2weeks yielded the greatest results. As the levels of anti-
Aβ antibodies increased in the patients’ serum and CSF, the level of Aβ increased in the 
serum and decreased in the CSF.22-27 These findings are consistent with the results of 
trials in mice.18,19  
There are also other important points to consider before IVIg can be determined 
an effective therapy for AD. As IVIg becomes an acceptable treatment for a broader 
range of medical conditions, concerns about availability and cost will arise. IVIg is 
currently an expensive treatment at an estimated $4551.25 per infusion.28 All of the IVIg 
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produced is currently used and strategies to cope with the increasing demand must be 
established.29 The exact correlation between Aβ levels and cognitive function in the 
patient remains unknown, and the Aβ load could not predict cognitive function. It is 
possible that other mechanisms of IVIg may by responsible for the observed 
improvement in AD patients.26,27  
Applying the GRADE criteria to each outcome in each study and then 
summarizing the total quality of evidence for each outcome revealed major defects. See 
Table 1. As a randomized clinical trial, the study began with a grade of high. Lack of 
precision from the small study group (n=24) resulted in a downgrade for the outcomes. 
Possible publication bias resulted in a second downgrade for the outcomes. Study 1 is 
graded as low quality of evidence. Study 2 was a non-randomized clinical trial. The 
precision deficit from a low number of subjects (n=8), lack of control group and blinding, 
and the high risk of recruitment bias resulted in a grade of very low. A dose response 
gradient was evident in Study 2, but the imprecision of those results make it insufficient 
evidence to upgrade the study. Study 3 was a non-randomized clinical trial. In this study, 
there was also a lack of precision with a low number of subjects (n=5), no control group 
or blinding, and a high risk of recruitment bias. There was also possible publication bias. 
Study 3 received a grade of very low for the outcomes. The absence of control groups for 
Study 2 and 3 resulted in an initial grade of very low and there was no basis for upgraded 
either study. 
Although the results of these initial studies are positive, many limitations are 
present in the current studies. The number of participants in each study is remarkably 
low. Two studies26,27 were not blinded, randomized, nor placebo-controlled. There is 
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potential bias associated with an open-label study design and with studies funded by 
corporations that produce the medication. Serious flaws in the studies available to date 
make the quality of current evidence very low overall. 
Research is currently moving forward on this topic. The Gammaglobulin 
Alzheimer’s Partnership (GAP) study is in progress. It is a randomized, double-blind, 
placebo-controlled, add-on three arm study aimed at investigating the efficacy of IVIg in 
the treatment of 360+ patients with mild to moderate AD over 18 months. The estimated 
completion date is February, 2013.27 
CONCLUSION 
  
 The evidence indicates that IVIg may be an effective treatment for patients with 
mild to moderate Alzheimer’s disease. A dose of 0.4g/kg/2weeks results in the best 
outcome regarding cognitive function. The use of IVIg stabilized or improved cognitive 
function over six months to three years in a severely limited number of patients. IVIg has 
resulted in the statistically significant increase in serum and CSF anti-Aβ antibodies, an 
increase in serum Aβ, and a decrease in CSF Aβ. The current studies are of very low 
quality according to the GRADE criteria.21 The high cost of IVIg and very low quality 
studies make it difficult to determine cost versus benefit at this time.  
 Further research to determine the mechanism of action of IVIg in Alzheimer’s 
disease is needed. Research to quantify the amount of CSF Aβ necessary to inhibit the 
accumulation of plaque would be beneficial. Also, larger, placebo-controlled, 
20 
randomized, double-blinded clinical trials conducted over an extended length of time to 
determine the efficacy of IVIg in AD are needed.  
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Table I: Characteristics of Reviewed Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aStudies 2 and 3 had lack of blinding, control group, and high risk for recruitment bias 
bVery small sample sizes (n=24, 8, and 5, respectively) 
cBaxter Corporation funded Studies 1 and 2 and makes Gammagard which was used in these studies 
 
 
 
 
 
 
 
 
 
 
 Downgrade Criteria 
Quality  
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Cognitive Function   
3 
 
1 RCT 
2 Non-
randomized 
Clinical Trials 
 Very 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
Bias 
possiblec 
Very low Critical 
Efficacy Measured by Aβ Load of Serum and CSF  
2 
2 Non-
randomized 
Clinical Trials 
Very 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
Bias 
possiblec 
Very low Important 
Safety Measured by Adverse Events  
3 
1 RCT 
2 Non-
randomized 
Clinical Trials 
Very 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
Bias 
possiblec 
Very low Important 
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Table II and III.  Results From Study 3: IVIg Against 
β-Amyloid For The Treatment of Alzheimer’s 
Disease 
Table II: Total Concentration of Aβ  
 Aβ CSF  Aβ Serum  
 Baseline 6 months Baseline 6 months 
Patient 1 427.2 241.4 292.1 624.3 
Patient 2 408.0 295.6 147.2 616.2 
Patient 3 418.8 319.8 192.7 592.7 
Patient 4 532.2 326.8 183.4 379.1 
Patient 5 549.0 453.8 386.5 580.2 
Table III: Results of Cognitive Testing 
 ADAS-cog  MMSE  Visuconstruction  
 Baseline 6 months Baseline 6 months Baseline 6 months 
Patient 1 34 32 16 20 25 50 
Patient 2 23.3 16.3 23 25 50 75 
Patient 3 47 41 11 12 0 25 
Patient 4 23.6 20.3 25 26 100 100 
Patient 5 29 29 22 22 75 75 
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Appendix A:  
Alzheimer Disease Diagnosis Criteria:  NINCDS-ADRDA 
I. Clinical Diagnosis of Probable Alzheimer’s Disease 
1. Dementia established by clinical examination and mental status testing and confirmed by 
neuropsychological testing 
2. Deficits in at least two cognitive domains 
3. Progressive cognitive decline, including memory 
4. Normal level of consciousness  
5. Onset between ages 40 and 90 (most common after 65) years 
6. No other possible medical or neurological explanation 
 
II. Probable Alzheimer’s Disease Supported by 
1. Progressive aphasia, apraxia, and agnosia 
2. Impaired activities of daily living 
3. Family history of similar disorder 
4. Brain atrophy on CT/MRI, especially if progressive 
5. Normal CSF, EEG (or nonspecifically abnormal)  
 
III. Other Clinical Features Consistent with Probable Alzheimer’s Disease 
1. Plateau in course 
2. Associated symptoms: depression; insomnia; incontinence; illusions; hallucinations; 
catastrophic verbal, emotional, or physical outbursts; sexual disorders; weight loss; 
during more advanced stages increased muscle tone, myoclonus, and abnormal gait 
3. CT normal for age 
 
IV. Features That Make Alzheimer’s Disease Uncertain or Unlikely 
1.    Acute onset 
2.    Focal sensorimotor signs 
3.    Seizures or gait disorder early in course 
 
V. Clinical Diagnosis of Possible Alzheimer’s Disease 
1. Dementia with atypical onset or course in the absence of another 
medical/neuropsychiatric explanation 
2. Dementia with another disease not felt otherwise to be the cause of dementia 
3. For research purposes, a progressive focal cognitive deficit 
 
VI. Definite Alzheimer’s Disease 
1. Meets clinical criteria for probable Alzheimer’s disease 
2. Tissue confirmation (autopsy or brain biopsy) 
 
 
 
